Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shigella vaccine + enterotoxigenic escherichia coli vaccine
- Development stage
- Preclinical
- Lead developer
- University of Maryland School of Medicine
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Emergent BioSolutions is developing a live attenuated vaccine candidate designed to provide dual protection against Shigellosis and Enterotoxigenic Escherichia coli (ETEC) infections. The vaccine utilizes a weakened Shigella strain as a vector to express specific ETEC antigens, aiming to stimulate a robust immune response against two of the primary bacterial causes of diarrheal disease worldwide. Intended primarily for traveler's health and populations in endemic regions, the project has been supported by research collaborations and funding agreements with the University of Maryland School of Medicine. As of the early 2020s, the vaccine candidate was positioned in the preclinical stage of development.
- Other names
- Shigella-ETEC vaccineLive attenuated Shigella-ETEC vaccineEmergent BioSolutions Shigella-ETEC vaccine
02
Targets
IpaB (Invasion plasmid antigen B)Shigella lipopolysaccharide antigenLTB (Heat-labile enterotoxin B subunit)CFA/I (Colonization factor antigen I)
Beyond the preview
Go deeper on shigella vaccine + enterotoxigenic escherichia coli vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shigella vaccine + enterotoxigenic escherichia coli vaccine.